Kirsi Taimen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kirsi Taimen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Laura Pirilä
Turku University Hospital: TYKS Turu yliopistollinen keskussairaala
5 shared publications- Laura Pirilä
Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital , Turku
3 shared publications - Laura Ryyppö
Turku University Hospital: TYKS Turu yliopistollinen keskussairaala
3 shared publications Marko Seppänen
Turku PET Centre: Turun PET keskus
3 shared publicationsAulikki Kononoff
Division of Medicine, University Hospital , Kuopio, Finland
2 shared publicationsHeikki Relas
Division of Rheumatology, Helsinki University Hospital, Helsinki University , Helsinki, Finland
2 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in Research Square
Comparison of diagnostic performance of [18F]FDG LAFOV and SAFOV PET/CT in Giant Cell Arteritis
- 19 March 2026
- Published by Springer Nature in Research Square
Open AccessComparison of diagnostic performance of [18F]FDG LAFOV and SAFOV PET/CT in Giant Cell Arteritis
- Open Access
- 10 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (2) , 151-153
Utility of cranial and cervical vessel magnetic resonance imaging as a diagnostic aid in a patient with suspected giant cell arteritis
- 10 September 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (2) , 151-153
Open AccessUtility of cranial and cervical vessel magnetic resonance imaging as a diagnostic aid in a patient with suspected giant cell arteritis
- Open Access
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf055
Giant cell arteritis in Finland from 2010 to 2020: incidence, developing diagnostic methods and disease presentation
Objectives: To study the annual incidence, diagnostic methods used and clinical presentation of giant cell arteritis (GCA) over time in Finland. Methods: Newly diagnosed GCA patients from 2010 to 2020 were retrospectively identified from four healthcare districts in Finland. Medical records were reviewed and data on incidence, diagnostic methods, phenotype [cranial vs large vessel (LV)-GCA] and clinical presentation were analysed. Results: We identified 602 newly diagnosed GCA patients. The annual incidence was 9.0 cases/100 000 persons (95% CI 8.3, 9.7) ≥50 years of age and was significantly higher in the period 2016–2020 compared with the period 2010–2015 [11.3 (95% CI 10.1, 12.5) vs 7.0 (95% CI 6.2, 7.9), P < 0.001]. Imaging- or biopsy-confirmed diagnosis was recorded in 75% of GCA patients, while 25% had a clinical diagnosis. The proportion of imaging- or biopsy-confirmed diagnoses increased over time [64.7% (2010–2015) vs 82.2% (2016–2020)] while that of clinical diagnoses decreased. The use of imaging methods increased while the use of temporal artery biopsies decreased between the two time periods. LV-GCA was discovered more often in the period 2016–2020 when compared with 2010–2015 (34.0% vs 19.3% of patients). Conclusion: The incidence of GCA increased during the study period, as well as the proportion of imaging- or biopsy-confirmed diagnoses, probably due to more frequent use of advanced imaging methods. Additionally, patients with LV-GCA were more commonly identified.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (2) , rkaf055
Open AccessGiant cell arteritis in Finland from 2010 to 2020: incidence, developing diagnostic methods and disease presentation
Objectives: To study the annual incidence, diagnostic methods used and clinical presentation of giant cell arteritis (GCA) over time in Finland. Methods: Newly diagnosed GCA patients from 2010 to 2020 were retrospectively identified from four healthcare districts in Finland. Medical records were reviewed and data on incidence, diagnostic methods, phenotype [cranial vs large vessel (LV)-GCA] and clinical presentation were analysed. Results: We identified 602 newly diagnosed GCA patients. The annual incidence was 9.0 cases/100 000 persons (95% CI 8.3, 9.7) ≥50 years of age and was significantly higher in the period 2016–2020 compared with the period 2010–2015 [11.3 (95% CI 10.1, 12.5) vs 7.0 (95% CI 6.2, 7.9), P < 0.001]. Imaging- or biopsy-confirmed diagnosis was recorded in 75% of GCA patients, while 25% had a clinical diagnosis. The proportion of imaging- or biopsy-confirmed diagnoses increased over time [64.7% (2010–2015) vs 82.2% (2016–2020)] while that of clinical diagnoses decreased. The use of imaging methods increased while the use of temporal artery biopsies decreased between the two time periods. LV-GCA was discovered more often in the period 2016–2020 when compared with 2010–2015 (34.0% vs 19.3% of patients). Conclusion: The incidence of GCA increased during the study period, as well as the proportion of imaging- or biopsy-confirmed diagnoses, probably due to more frequent use of advanced imaging methods. Additionally, patients with LV-GCA were more commonly identified.
- Open Access
- 7 June 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (3) , rkae095
Polyarteritis nodosa with abdominal bleeding: imaging with PET/CT and angiography on the same day
A 59-year-old male with seropositive rheumatoid arthritis, hypertension and anticoagulation due to past pulmonary embolism was hospitalized for fever (39°C) and myalgia. His CRP level was 190 mg/l and he had haematuria and proteinuria, but infection screening and ANCA remained negative. One week after admission he experienced a sudden life-threatening abdominal catastrophe. 18F fluorodeoxyglucose (FDG)-PET/CT was performed earlier on the same day, before the abdominal symptoms appeared. PET/CT detected increased FDG uptake in the peri- and intramuscular arterial tree of the lower extremities, indicating vasculitis in middle-sized arteries, as well as inhomogeneous uptake in the liver ( Fig. 1A). During the abdominal crisis, the CT scan showed haematoma and active bleeding of the right liver lobe ( Fig. 1B). Digital subtraction angiography revealed multiple hepatic artery microaneurysms and stenoses ( Fig. 1C). These findings were consistent with polyarteritis nodosa (PAN). He underwent successful emergency hepatic arterial embolization and was later treated with a molecular adsorbent recirculating system (MARS) for temporary liver failure. Immunosuppression was started with methylprednisolone and cyclophosphamide. Hepatitis serology was negative. Subsequent genetic testing for UBA1 and ADA2 was normal.
- 7 June 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (3) , rkae095
Open AccessPolyarteritis nodosa with abdominal bleeding: imaging with PET/CT and angiography on the same day
A 59-year-old male with seropositive rheumatoid arthritis, hypertension and anticoagulation due to past pulmonary embolism was hospitalized for fever (39°C) and myalgia. His CRP level was 190 mg/l and he had haematuria and proteinuria, but infection screening and ANCA remained negative. One week after admission he experienced a sudden life-threatening abdominal catastrophe. 18F fluorodeoxyglucose (FDG)-PET/CT was performed earlier on the same day, before the abdominal symptoms appeared. PET/CT detected increased FDG uptake in the peri- and intramuscular arterial tree of the lower extremities, indicating vasculitis in middle-sized arteries, as well as inhomogeneous uptake in the liver ( Fig. 1A). During the abdominal crisis, the CT scan showed haematoma and active bleeding of the right liver lobe ( Fig. 1B). Digital subtraction angiography revealed multiple hepatic artery microaneurysms and stenoses ( Fig. 1C). These findings were consistent with polyarteritis nodosa (PAN). He underwent successful emergency hepatic arterial embolization and was later treated with a molecular adsorbent recirculating system (MARS) for temporary liver failure. Immunosuppression was started with methylprednisolone and cyclophosphamide. Hepatitis serology was negative. Subsequent genetic testing for UBA1 and ADA2 was normal.
- 14 May 2024
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (4) , 269-275
Causes and predictors of death among Finnish patients with systemic sclerosis
ObjectiveThe aim of this study was to assess causes and predictors of death among Finnish patients with systemic sclerosis (SSc).MethodMedical records of patients registered with the ICD-10 code M34 from 1996 to 2018 in two university hospitals were reviewed retrospectively. Clinical data were collected until the end of 2020. Death certificates were obtained from Statistics Finland up to August 2021. Using death certificates and patient records, the cause of death for each patient was determined. The mean age at death, median time from SSc diagnosis, and factors predicting death were analysed.ResultsAmong 313 SSc patients, 91 deaths occurred between April 2000 and September 2020. Overall 5 and 10 year survival rates were 88.4% and 80.2%, respectively. SSc was the most common primary cause of death (n = 35) and interstitial lung disease (ILD) was the most common SSc-related cause of death (n = 13). Moreover, 52% of the patients with diffuse SSc and 33% of those with limited cutaneous SSc died as a result of SSc itself. Patients who died because of SSc were significantly younger [mean +/- sd age 65.6 +/- 12.7 years, 95% confidence interval (CI) 61.2-70.1] than those who died from other causes (74.2 +/- 9.6 years, 95% CI 71.5-76.9) (p = 0.0006). ILD, pulmonary arterial hypertension, gastrointestinal involvement, male gender, and older age at disease onset predicted death.ConclusionThe disease itself was the major cause of death among Finnish SSc patients, in both diffuse and limited forms of SSc.
- 14 May 2024
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 53 (4) , 269-275
Causes and predictors of death among Finnish patients with systemic sclerosis
ObjectiveThe aim of this study was to assess causes and predictors of death among Finnish patients with systemic sclerosis (SSc).MethodMedical records of patients registered with the ICD-10 code M34 from 1996 to 2018 in two university hospitals were reviewed retrospectively. Clinical data were collected until the end of 2020. Death certificates were obtained from Statistics Finland up to August 2021. Using death certificates and patient records, the cause of death for each patient was determined. The mean age at death, median time from SSc diagnosis, and factors predicting death were analysed.ResultsAmong 313 SSc patients, 91 deaths occurred between April 2000 and September 2020. Overall 5 and 10 year survival rates were 88.4% and 80.2%, respectively. SSc was the most common primary cause of death (n = 35) and interstitial lung disease (ILD) was the most common SSc-related cause of death (n = 13). Moreover, 52% of the patients with diffuse SSc and 33% of those with limited cutaneous SSc died as a result of SSc itself. Patients who died because of SSc were significantly younger [mean +/- sd age 65.6 +/- 12.7 years, 95% confidence interval (CI) 61.2-70.1] than those who died from other causes (74.2 +/- 9.6 years, 95% CI 71.5-76.9) (p = 0.0006). ILD, pulmonary arterial hypertension, gastrointestinal involvement, male gender, and older age at disease onset predicted death.ConclusionThe disease itself was the major cause of death among Finnish SSc patients, in both diffuse and limited forms of SSc.
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (2) , rkad050
Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study
To investigate the effect of tumor necrosis factor inhibitor (TNFi) initiation on working ability and health care resource utilization among axial spondyloarthritis patients in a real-life setting. Patients with a clinical diagnosis of non-radiographic (nr-axSpA) or radiographic axial spondyloarthritis initiating their first TNFi were identified from the ROB-FIN registry. Sickness absences, including sick leaves and disability pensions, in- and outpatient days and rehabilitation rates one year before and after initiating the medication were retrieved from national registries. Factors affecting result variables were studied using multivariate regression analysis. Overall, 787 patients were identified. Rates of work disability days per year were 55.6 the year before treatment onset and 55.2 the year after, with significant differences between patient subgroups. The rate of sick leaves decreased after starting TNFi treatment. However, the rate of disability pensions continued to rise. Patients with the diagnosis of non-radiographic axial spondyloarthritis experienced decrease in overall work disability and especially fewer sick leaves. No gender differences were detected. The TNFis interrupt the increase in work disabled days evident during the year prior to their initiation. However, the overall work disability remains high. Treating patients earlier in the nr-axSpA phase regardless of gender appears important in maintaining work ability. What does this mean for patients? Maintaining patients’ ability to work is a complex and challenging task that deserves special attention when treating people with chronic inflammatory diseases, such as ankylosing spondylitis and non-radiographic spondyloarthritis (nr-axSpA). Work disability remains a problem among these patients despite the evolving treatment options. We investigated how a type of drug called tumour necrosis factor inhibitor (TNFi) affects working ability in people with nr-axSpA in a real-life setting in Finland. We used data on patients and their treatment from a database called the National Register for Antirheumatic and Biologic Treatment in Finland. We compared data on sick leave, in- and outpatient days and rehabilitation one year before and after starting TNFi medication. Our results show that TNFi medication substantially reduces the amount of sick leave patients need to take, especially for people with nr-axSpA. However, we found that the amount of disability pension claimed rises steadily despite patients starting TNFi medication. Taking these results together, we conclude that starting TNFi medication may interrupt nr-axSpA patients’ decline in work ability. However, effective ways of maintaining patients’ ability to work are still needed.
- 1 January 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (2) , rkad050
Open AccessImpact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study
To investigate the effect of tumor necrosis factor inhibitor (TNFi) initiation on working ability and health care resource utilization among axial spondyloarthritis patients in a real-life setting. Patients with a clinical diagnosis of non-radiographic (nr-axSpA) or radiographic axial spondyloarthritis initiating their first TNFi were identified from the ROB-FIN registry. Sickness absences, including sick leaves and disability pensions, in- and outpatient days and rehabilitation rates one year before and after initiating the medication were retrieved from national registries. Factors affecting result variables were studied using multivariate regression analysis. Overall, 787 patients were identified. Rates of work disability days per year were 55.6 the year before treatment onset and 55.2 the year after, with significant differences between patient subgroups. The rate of sick leaves decreased after starting TNFi treatment. However, the rate of disability pensions continued to rise. Patients with the diagnosis of non-radiographic axial spondyloarthritis experienced decrease in overall work disability and especially fewer sick leaves. No gender differences were detected. The TNFis interrupt the increase in work disabled days evident during the year prior to their initiation. However, the overall work disability remains high. Treating patients earlier in the nr-axSpA phase regardless of gender appears important in maintaining work ability. What does this mean for patients? Maintaining patients’ ability to work is a complex and challenging task that deserves special attention when treating people with chronic inflammatory diseases, such as ankylosing spondylitis and non-radiographic spondyloarthritis (nr-axSpA). Work disability remains a problem among these patients despite the evolving treatment options. We investigated how a type of drug called tumour necrosis factor inhibitor (TNFi) affects working ability in people with nr-axSpA in a real-life setting in Finland. We used data on patients and their treatment from a database called the National Register for Antirheumatic and Biologic Treatment in Finland. We compared data on sick leave, in- and outpatient days and rehabilitation one year before and after starting TNFi medication. Our results show that TNFi medication substantially reduces the amount of sick leave patients need to take, especially for people with nr-axSpA. However, we found that the amount of disability pension claimed rises steadily despite patients starting TNFi medication. Taking these results together, we conclude that starting TNFi medication may interrupt nr-axSpA patients’ decline in work ability. However, effective ways of maintaining patients’ ability to work are still needed.
- Open Access
- 6 August 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 1015-1025
Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.
- 6 August 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 1015-1025
Open AccessImmunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.
- Open Access
- 14 December 2020
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 8 (1) , 233-242
The Delay and Costs of Diagnosing Systemic Vasculitis in a Tertiary-Level Clinic
Introduction The diagnosis of systemic vasculitis is a challenge because of the heterogeneity of clinical manifestations. The aim of this study is to analyze the diagnostic delay in systemic vasculitis, the total costs during the first year of care, and how the diagnostic delay affects the costs in a tertiary health care facility. Methods Patients with a new diagnosis of systemic vasculitis between 2010 and 2018 were identified from hospital records. The diagnostic delay and health care costs were evaluated during the diagnostic period and within 12 months after the first contact with tertiary health care. Vasculitis-related costs were recorded as true costs charged. A total of 317 patients fulfilled the study criteria. The diagnoses were grouped into three clinically relevant groups: IgA vasculitis and other small-vessel vasculitis (n = 64), ANCA-associated vasculitis (AAV) (n = 112), and large-vessel vasculitis (LVV) (n = 141). Results The diagnostic delay from the first referral to tertiary-level clinic was shortest in the LVV group and longest in the AAV group. Total costs during the diagnostic period were the highest in the AAV group (median = €6754 [IQR €8812]) and lowest in the LVV group (median = €3123 [IQR €4517]), p < 0.001. There was a significant positive correlation between the diagnostic delay and total costs during the diagnostic period and 12 months (rs = 0.38, p < 0.001 and rs = 0.34, p < 0.001, respectively). In a linear model, the inpatient days and the number of laboratory tests were the strongest predictors (p < 0.001) of a higher treatment cost during the diagnostic period. Conclusions There is a substantial diagnostic delay that correlates significantly with the costs in tertiary-level health care when diagnosing systemic vasculitis.
- 14 December 2020
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 8 (1) , 233-242
Open AccessThe Delay and Costs of Diagnosing Systemic Vasculitis in a Tertiary-Level Clinic
Introduction The diagnosis of systemic vasculitis is a challenge because of the heterogeneity of clinical manifestations. The aim of this study is to analyze the diagnostic delay in systemic vasculitis, the total costs during the first year of care, and how the diagnostic delay affects the costs in a tertiary health care facility. Methods Patients with a new diagnosis of systemic vasculitis between 2010 and 2018 were identified from hospital records. The diagnostic delay and health care costs were evaluated during the diagnostic period and within 12 months after the first contact with tertiary health care. Vasculitis-related costs were recorded as true costs charged. A total of 317 patients fulfilled the study criteria. The diagnoses were grouped into three clinically relevant groups: IgA vasculitis and other small-vessel vasculitis (n = 64), ANCA-associated vasculitis (AAV) (n = 112), and large-vessel vasculitis (LVV) (n = 141). Results The diagnostic delay from the first referral to tertiary-level clinic was shortest in the LVV group and longest in the AAV group. Total costs during the diagnostic period were the highest in the AAV group (median = €6754 [IQR €8812]) and lowest in the LVV group (median = €3123 [IQR €4517]), p < 0.001. There was a significant positive correlation between the diagnostic delay and total costs during the diagnostic period and 12 months (rs = 0.38, p < 0.001 and rs = 0.34, p < 0.001, respectively). In a linear model, the inpatient days and the number of laboratory tests were the strongest predictors (p < 0.001) of a higher treatment cost during the diagnostic period. Conclusions There is a substantial diagnostic delay that correlates significantly with the costs in tertiary-level health care when diagnosing systemic vasculitis.
- Open Access
- 1 January 2020
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 4 (1) , rkaa004
Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review
Objective: Patients receiving chemotherapy are prone to neutropoenic infections, presenting with non-specific symptoms such as a high fever and elevated inflammatory parameters. Large-vessel vasculitis (LVV) may have a similar clinical presentation and should be included in differential diagnostics. A few published case reports and adverse event reports suggest a causal association between LVV and the use of granulocyte colony-stimulating factor (G-CSF) and chemotherapy. Our objective was to evaluate the relationship between LVV, G-CSF and chemotherapy. Methods: Between 2016 and 2018, we identified six patients in Finland with probable drug-induced LVV associated with G-CSF and chemotherapy. All six patients had breast cancer. A systematic literature review was performed according to PRISMA guidelines using comprehensive search terms for cancer, chemotherapy, G-CSF and LVV. Results: The literature search identified 18 similar published case reports, of which most were published after 2014. In all patients combined (n = 24), the time delay from the last drug administration to the LVV symptoms was on average 5 days with G-CSF (range = 1–8 days) and 9 days with chemotherapy (range = 1–21 days). Common symptoms were fever (88%), neck pain (50%) and chest pain (42%). Based on imaging, 17/24 (71%) had vascular inflammation in the thoracic aorta and supra-aortic vessels, but 5/24 (21%) reportedly had inflammation limited to the carotid area. Conclusion: This review suggests that LVV may be a possible serious adverse event associated with G-CSF and chemotherapy. Successful management of drug-induced LVV requires early identification, through diagnostic imaging, and discontinuation of the drug.
- 1 January 2020
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 4 (1) , rkaa004
Open AccessGranulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review
Objective: Patients receiving chemotherapy are prone to neutropoenic infections, presenting with non-specific symptoms such as a high fever and elevated inflammatory parameters. Large-vessel vasculitis (LVV) may have a similar clinical presentation and should be included in differential diagnostics. A few published case reports and adverse event reports suggest a causal association between LVV and the use of granulocyte colony-stimulating factor (G-CSF) and chemotherapy. Our objective was to evaluate the relationship between LVV, G-CSF and chemotherapy. Methods: Between 2016 and 2018, we identified six patients in Finland with probable drug-induced LVV associated with G-CSF and chemotherapy. All six patients had breast cancer. A systematic literature review was performed according to PRISMA guidelines using comprehensive search terms for cancer, chemotherapy, G-CSF and LVV. Results: The literature search identified 18 similar published case reports, of which most were published after 2014. In all patients combined (n = 24), the time delay from the last drug administration to the LVV symptoms was on average 5 days with G-CSF (range = 1–8 days) and 9 days with chemotherapy (range = 1–21 days). Common symptoms were fever (88%), neck pain (50%) and chest pain (42%). Based on imaging, 17/24 (71%) had vascular inflammation in the thoracic aorta and supra-aortic vessels, but 5/24 (21%) reportedly had inflammation limited to the carotid area. Conclusion: This review suggests that LVV may be a possible serious adverse event associated with G-CSF and chemotherapy. Successful management of drug-induced LVV requires early identification, through diagnostic imaging, and discontinuation of the drug.
- Open Access
- 29 August 2019
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2019, 1-8
The Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment
18F-Fluorodeoxyglucose positron-emission tomography (18F-FDG-PET) with computed tomography (CT) is effective for diagnosing large vessel vasculitis, but its usefulness in accurately diagnosing suspected, unselected vasculitis remains unknown. We evaluated the feasibility of 18F-FDG-PET/CT in real-life cohort of patients with suspicion of vasculitis. The effect of the dose and the timing of glucocorticoid (GC) medication on imaging findings were in special interest. 82 patients with suspected vasculitis were evaluated by whole-body 18F-FDG-PET/CT. GC treatment as prednisolone equivalent doses at the scanning moment and before imaging was evaluated. 38/82 patients were diagnosed with vasculitis. Twenty-one out of 38 patients had increased 18F-FDG accumulation in blood vessel walls indicating vasculitis in various sized vessels. Vasculitis patients with a positive vasculitis finding in 18F-FDG-PET/CT had a significantly shorter duration of GC use (median = 4.0 vs 7.0 days, ), and they used lower GC dose during the PET scan (median dose = 15.0 mg/day vs 40.0 mg/day, ) compared to 18F-FDG-PET/CT-negative patients. Vasculitis patients with a positive 18F-FDG-PET/CT result had significantly higher C-reactive protein (CRP) than patients with a negative 18F-FDG-PET/CT finding (mean value = 154.5 vs 90.4 mg/L, ). We found that 18F-FDG-PET/CT positivity was significantly associated with a lower dose and shorter duration of GC medication and higher CRP level in vasculitis patients. 18F-FDG-PET/CT revealed clinically significant information in over half of the patients and was effective in confirming the final diagnosis.- 29 August 2019
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2019, 1-8
Open AccessThe Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment
18F-Fluorodeoxyglucose positron-emission tomography (18F-FDG-PET) with computed tomography (CT) is effective for diagnosing large vessel vasculitis, but its usefulness in accurately diagnosing suspected, unselected vasculitis remains unknown. We evaluated the feasibility of 18F-FDG-PET/CT in real-life cohort of patients with suspicion of vasculitis. The effect of the dose and the timing of glucocorticoid (GC) medication on imaging findings were in special interest. 82 patients with suspected vasculitis were evaluated by whole-body 18F-FDG-PET/CT. GC treatment as prednisolone equivalent doses at the scanning moment and before imaging was evaluated. 38/82 patients were diagnosed with vasculitis. Twenty-one out of 38 patients had increased 18F-FDG accumulation in blood vessel walls indicating vasculitis in various sized vessels. Vasculitis patients with a positive vasculitis finding in 18F-FDG-PET/CT had a significantly shorter duration of GC use (median = 4.0 vs 7.0 days, ), and they used lower GC dose during the PET scan (median dose = 15.0 mg/day vs 40.0 mg/day, ) compared to 18F-FDG-PET/CT-negative patients. Vasculitis patients with a positive 18F-FDG-PET/CT result had significantly higher C-reactive protein (CRP) than patients with a negative 18F-FDG-PET/CT finding (mean value = 154.5 vs 90.4 mg/L, ). We found that 18F-FDG-PET/CT positivity was significantly associated with a lower dose and shorter duration of GC medication and higher CRP level in vasculitis patients. 18F-FDG-PET/CT revealed clinically significant information in over half of the patients and was effective in confirming the final diagnosis.